Paul B Fitzgerald
Paul B Fitzgerald, MBBS, PhD is an expert in Psychiatry at Australian National University (Australia). As of October 2026, ScienceLeadR ranks Paul B Fitzgerald in the top 1% of experts worldwide for Depressive Disorder. Paul B Fitzgerald has authored 674 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 1 of them ongoing. SLR score: 2,122 (community average: 125). How the SLR is computed.
LeadR Profile
Psychiatry
Subspecialties: Neurology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD. He has conducted an extensive series of clinical trials and experimental studies developing new treatments for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease. He now leads an innovative School of Medicine and Psychology developing education and research programs integrating these traditionally diverse health disciplines. He is engaged in the conduct of a variety of clinical trials through ANU and through Paratus Clinical.
Organizations
Career arc: 2002 - 2026
Number : 674
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| TMS-EEG Correlate of Suicidal Ideation in Individuals with Depression: A Multi-Site Synthesis. PMID 42731592 — depression, multiple chronic conditions, suicidal ideation | Brain Stimul | 2026 | 0 |
| No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study. PMID 42490582 — memory, short-term, n-methyl-3,4-methylenedioxyamphetamine, pharmaceutical preparations, psilocybin, electrodes, electroencephalography, hallucinogens, memory, cognition | J Psychopharmacol | 2026 | 0 |
| Is there a place for non-invasive brain stimulation in the treatment of schizophrenia? PMID 42489431 — transcranial direct current stimulation, brain, transcranial magnetic stimulation, signs and symptoms, schizophrenia, therapeutics, psychiatry | Aust N Z J Psychiatry | 2026 | 0 |
| Beyond spectral power and connectivity: Electroencephalographic (EEG) travelling waves reveal altered spatiotemporal dynamics after traumatic brain injury (TBI). PMID 42419626 — brain injuries, brain, brain injuries, traumatic, psychiatry | Prog Neuropsychopharmacol Biol Psychiatry | 2026 | 1 |
| Global prevalence and disability burden of brain disorders: Impact of neurological, mental, and substance use disorders. PMID 42269957 — pharmaceutical preparations, mental disorders, brain, brain diseases, prevalence, anxiety disorders, nervous system diseases, neurology | Neurosci Biobehav Rev | 2026 | 0 |
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Maintenance rTMS for Depression (Maitr De) NCT06938841 — depression, safety, placebos, transcranial magnetic stimulation, maintenance, depressive disorder, therapeutics, depressive disorder, treatment-resistant, depressive disorder, major | N/A | Recruiting | 2025 |
LeadR Networks
Main global connection map